Clinical trials provide critical evidence for evaluating whether new drugs and treatments are safe and effective. Including a diverse and representative patient population in clinical trials is fundamental to ensuring that all communities benefit from innovation in medicine.
New federal requirements which Congress enacted as part of the Food and Drug Omnibus Reform Act (FDORA) may help engage patients across a range of identities and racial and ethnic populations that have been historically excluded or underrepresented in research. As policymakers weigh additional options for advancing diversity in clinical trials, they may consider emerging strategies to reduce barriers to participation, increase trial accessibility, and support effective multi-sector collaboration.
This webinar provided an overview of new approaches for equitable clinical trial design, identified opportunities for leveraging technology and scaling community-based partnerships, and explored potential policy levers for promoting diversity and inclusion in clinical trials.
This virtual event was sponsored by Amgen, Patient-Centered Outcomes Research Institute (PCORI), Walgreens, and Genentech.
- Clay Alspach, Principal, Leavitt Partners
- Courtney Christian, Deputy Vice President, Policy and Research, Health Equity, PhRMA
- Ricki Fairley, President and CEO, TOUCH, Black Breast Cancer Alliance
- Craig Lipset, Co-Chair, Decentralized Trials & Research Alliance
- Fabian Sandoval, MD, President and CEO, Emerson Clinical Research Institute (ECRI)
- Moderated by: Gary Puckrein, President and CEO, National Minority Quality Forum